19 results about "Uridine" patented technology

The invention discloses a multi-emission composite nano ratiometric fluorescent probe for detecting fluoroquinolone antibiotics and a preparation method of the multi-emission composite nano ratiometric fluorescent probe. The CdTe-Tb-UMP composite nano ratiometric fluorescent probe with double ligands is prepared by taking metal terbium ions (Tb < 3 + >) as central ions and respectively taking uridine monophosphate (UMP) and CdTe quantum dots with red fluorescence emission as bridged ligands. ENR is further coordinated with Tb < 3 + >, energy is transferred to Tb < 3 + > through an antenna effect, so that characteristic green fluorescence of Tb < 3 + > is turned on, and fluorescence of CdTe quantum dots is almost kept unchanged. On the basis, a portable nursing point testing system is further constructed, and the portable nursing point testing system comprises an intelligent mobile phone detector and a wearable fingertip sensor integrated with a micro-fluidic chip and is used for on-site rapid detection of the ENR. The paper-based chip shows rapid and sensitive fluorescence response, and the detection limits of the spectrograph and the paper-based sensor on the ENR are 4.7 nM and 13.1 nM respectively. The probe can be applied to detection of ENR in actual environment water samples, food and drugs.

The present invention relates to a photosensitive RNA cytidine base editor and use thereof. The photosensitive RNA cytidine base editor can cause deamination of cytidine (C) in a target double-stranded RNA to uridine (U), thereby achieving editing of C to U. The photosensitive RNA cytidine base editor comprises: (1) a dCas-eADAR2dd N-pMagHigh fusion protein, and (2) an nMagHigh-eADAR2dd C fusion protein.

The invention relates to the technical field of biology, and discloses a recombinant N-acetylglucosamine-1-phosphate uridine transferase (GlmU) mutant and a preparation method thereof. The sequence of the recombinase is formed by connecting an N-acetylglucosamine-1-uridine phosphate transferase (GlmU) mutant (L113V-V172I) from Azotobacter chroococcum, an N-terminal histidine tag (His-tag) and a small ubiquitin-like modified protein tag (SUMO-tag) in series. The invention further discloses a preparation method of the recombinase. Compared with a recombinant wild type N-acetylglucosamine-1-uridine phosphate transferase with the same source, the recombinant N-acetylglucosamine-1-uridine phosphate transferase mutant has higher activity which is 1.5 times of that of the recombinant wild type and higher stability, and the residual activity of the mutant is 66.5% after the mutant is placed at room temperature for 5 days, so that the mutant has a good application prospect in the field of N-acetylglucosamine-1-uridine phosphate transferase. And the soluble expression quantity of the recombinant mutant N-acetylglucosamine-1-uridine phosphate transferase is increased by 5 times.

The application provides a radix isatidis granule and a preparation method thereof, which is prepared from the following components in parts by weight: radix isatidis 700 parts, sucrose 170-190 parts and dextrin 50-70 parts. The content of active ingredient (R,S)-deoxyschizandrin, the total content of uridine, guanosine and adenosine, and the content of indirubin in the prepared radix isatidis granule are significantly improved, and the quality is stable after being accelerated for 6 months.

Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and / or one or more abasic spacers and / or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hematological disorder, liver disease, or hepatic fibrosis, comprising administering to a subject diagnosed with said telomere biology disorder a therapeutically effective amount of said compounds.

The present application relates to a kind of preparation method of triphosphoryl uridine trisodium and its preparation.The present application uses ionic liquid as reaction solvent, 2-chloro-4H-1,3,2-benzene dioxaphosphorin-4-ketone (compound 1) is reacted with tributylammonium pyrophosphate to generate cyclic intermediate 2, then uridine is reacted, and then it is obtained by oxidation, basic hydrolysis ring-opening step triphosphoryl uridine trisodium.The present application uses ionic liquid as solvent to promote the site selectivity of the hydroxyl group in the ribose structure of uridine in the reaction, which can make the reaction intermediate 2 react with the hydroxyl group of the 5' position of uridine with high selectivity, so as to obtain UTP with high yield, and the present application also prepares UTP into the form of trisodium salt to facilitate purification and preservation.The present application solves the problems of long steps and low yield in the prior art when using chemical synthesis method to synthesize UTP.

The present application relates to a kind of RNA base editing method and editing tool for recruiting endogenous APOBEC family enzyme by APOBEC recruiting guide RNA (APOBEC-recruiting guide RNA, rgRNA) to convert target cytosine into uridine. The rgRNA includes: at least one APOBEC recruiting domain and at least one programmable antisense region, when the rgRNA is combined with the target RNA, an editing loop that induces a circular single-stranded structure on the target RNA sequence. In the way of "catch recruit execute", accurate and flexible base conversion is realized, and the boundary of RNA editing in gene regulation and therapeutic application is expanded.

Compositions and methods comprising an artificial poly (A) sequence having at least one cytosine and at least one uridine and / or guanosine are provided.

The invention relates to C2 '-alkyl substituted nucleoside which comprises at least one of C2'-alkyl substituted thymidine, C2 '-alkyl substituted uridine, C2'-alkyl substituted adenosine and C2 '-alkyl substituted guanosine. The structure of the C2 '-alkyl substituted nucleoside is shown as a formula I or a formula II; the structure of the C2 '-alkyl substituted uridine is shown as a formula III in the specification; the structure of the C2 '-alkyl substituted adenosine is shown as a formula IV; the structure of the C2 '-alkyl substituted guanosine is shown as a formula V. The invention also relates to a preparation method of the C2 '-alkyl substituted nucleoside. According to the C2 '-alkyl substituted nucleoside and the preparation method thereof, the limitation of the prior art on functional group compatibility and operation convenience can be broken through, and the synthesis path of the C2'-alkyl substituted nucleoside can be enriched, so that the research and development process of oligonucleotide drugs is greatly promoted.

The invention provides a method for supporting operable activities in daily life by providing a combination of (a) long chain polyunsaturated fatty acids - in particular DHA and / or EPA - with (b) a nucleoside or nucleotide - in particular uridine or an equivalent thereof. The operable activities include eating; walking; toileting; bathing; grooming; dressing; using a communication device; having a conversation; going to an appointment; using a household appliance; washing dishes; cooking or preparing a beverage; writing; reading; doing household chores independently; carrying or shopping.

The present invention provides methylcytosine selective deaminases, compositions, kits, and methods of using the thereof, including sequencing methods involving: (a) contacting a DNA substrate comprising cytosine (C) and at least one methylcytosine nucleobase selected from 5-methylcytosine (5mC) and 5-hydroxymethylcytosine, or comprising C and both 5mC and 5hmC, with a methylcytosine selective deaminase to produce a deamination product, wherein the methylcytosine selective deaminase (i) is capable of deaminating 5mC to thymidine (T) and / or deaminating 5hmC to hydroxymethyluridine (hmU), and (ii) preferentially deaminating at least one methylcytosine nucleobase relative to cytosine (C); and (b) sequencing the deamination product, or amplifying the deamination product to produce an amplification product, and sequencing the amplification product to produce a sequence read in each case, wherein the position of C and the position of at least one methylcytosine nucleobase in the DNA substrate are determined based on the sequence read.

The invention discloses an N-acetylglucosamine transferase mutant and application thereof in production of L-tryptophan, and belongs to the technical field of genetic engineering. In order to solve the problems of yield limitation and the like caused by excessive consumption of phosphoenolpyruvic acid in the production of L-tryptophan, the invention weakens a phosphoprotein coding gene crr on escherichia coli; meanwhile, a uridine diphosphate galactose pyranose mutase gene glf and a glucokinase gene glk of the pseudomonas mobilis and an endogenous galactose H (+) transporter enzyme gene galP of escherichia coli are integrated at a pflB site, and a genetically engineered bacterium is obtained; mutagenesis is carried out on the basis to obtain a mutant strain with improved L-tryptophan yield; and the N-acetylglucosamine transferase mutants nagC and nagE are obtained by virtue of sequencing. Fermentation proves that overexpression of the mutant nagC or nagE or simultaneous overexpression of the mutants nagC and nagE in the genetically engineered bacteria can improve the yield of L-tryptophan.

The present invention relates to a compound of Formula (I):or a stereoisomer, solvate, tautomer or pharmaceutically acceptable salt thereof, wherein X, W1, W2, Y, Z, R1, R2 and R3 are as defined in the disclosure herein, for use in therapy, particularly for use in the treatment of cancer. The present invention also relates to methods of treating cancer comprising the administration of a compound of Formula (I) to asubject in need thereof, and to pharmaceutical compositions and kits comprising such compounds.

The invention discloses a novel extended furan [3, 2-d] uridine analogue as well as synthesis and application thereof, and belongs to the field of biological medicine and detection. The invention provides a furan [3, 2-d] uridine analogue with the following structure, and the furan [3, 2-d] uridine analogue has excellent fluorescent property, can be used as a fluorescent probe, such as a polarity detection probe, a pH detection probe, a DNA fluorescent probe and the like, and is widely applied to the fields of biochemistry, medicine and the like.

The present disclosure provides polyribonucleotides, in particular polyribonucleotides, which comprise deuterated adenosine, cytidine, guanosine, and / or uridine residues and which show reduced immunogenicity and / or enhanced expression, and methods of using such polyribonucleotides for the therapy of diseases.

The invention provides a yeast hydrolysate as well as a preparation method and application thereof, the yeast hydrolysate comprises the following components in percentage by mass: 35-65% of true protein, aromatic amino acid and sulfur-containing amino acid, and the content ratio of the aromatic amino acid to the sulfur-containing amino acid is 2-5; the ratio of the content of the components with the weight-average molecular weight of 200-2000Da to the content of the components with the weight-average molecular weight of more than 2000Da is 4-10, and the ratio of the content of the components with the weight-average molecular weight of 200-2000Da to the content of the components with the weight-average molecular weight of less than 200Da is 4-9; the yeast hydrolysate further comprises disodium nucleotide, the disodium nucleotide comprises disodium inosinate, disodium guanylate, disodium cytidine monophosphate and disodium uridinemonophosphate, and the ratio of the mass sum of the disodium inosinate and the disodium guanylate to the mass sum of the disodium cytidine monophosphate and the disodium uridinemonophosphate to the disodium nucleotide is 1: (0.6-1.2): (1.6-2.2). The feed additive is beneficial for further improving the feed intake of the piglets and reducing the disease incidence of the piglets.

The disclosure provides for the culture media particularly suitable to culture primary ostrich PGCs. The culture media contain specific growth factors and compounds that provide support for the growth and proliferation of ostrich PGCs. In certain embodiments, the culture media contain a basal culture medium and β-mercaptoethanol, cholesterol, FGF1, FGF2, BMP4, and IGF1. In some embodiments, the basal culture medium contains knock-out DMEM, B27 Supplement, MEM-MEAA, L-alanyl-L-glutamine dipeptide, cytidine, guanosine, uridine, adenosine, thymidine, sodium pyruvate, ovalbumin, sodium heparin, calcium chloride, ovotransferrin, and an antibiotic. The disclosure also includes methods and kits for producing such media as well as methods of culturing cells.

The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hair-pin or stem-loop structure, and wherein said oligonucleotide comprises a cytidine (a non-complementary nucleotide) or a uridine in a position opposite to the target adenosine to be edited in the target RNA region.